Stock Ratings / Health Care / MPLT / news

OVID (40) CTMX (20) PHAT (46) EOLS (21) ⌘ Pro Terminal →

Why MPLT Stock dropped -3.26% Today — RQD Quant Desk Flash

Q: Is MPLT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, MapLight Therapeutics Inc. (NASDAQ: MPLT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $7.72 (-3.26% 1D, market cap $500.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MPLT ranks #668 in composite RQD confidence.

Q: How does MPLT compare to OVID and CTMX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MPLT carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.4%. By comparison, OVID (Ovid Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -28.5%, cap $500.0M) and CTMX (CytomX Therapeutics Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -20.5%, cap $499.0M). Among the 5-stock peer group, MPLT leads on earnings multiple (N/A) while CTMX leads on capital efficiency (-20.5% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for MPLT?

Per MPLT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001770069), MapLight Therapeutics Inc. generated $0 in revenue, -$161.2M in net income, and -$138.6M in free cash flow against $479.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is MPLT trading relative to its 50-day, 200-day, and 52-week technical levels?

MPLT last traded at $7.72 (-3.26% on volume of 156,739 shares), positioning the stock -26.12% below its 50-day simple moving average ($10.45) and -62.38% below its 200-day simple moving average ($20.52). Across its 52-week range of $7.44 to $40.43, MPLT sits at the 0.8% percentile with a 14-day RSI of 31.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($6.76 to $8.68).

Q: Why is MPLT stock moving today?

Why MPLT Stock dropped -3.26% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.

$7.72 -3.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

MapLight Therapeutics Inc. (MPLT) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $500.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MPLT)Realized 20D OHLCV Swing Band: ±12.5%

AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why MPLT Stock dropped -3.26% Today — RQD Quant Desk Flash

MapLight Therapeutics Inc. (MPLT) dropped -3.26% to $7.72, trading at 2% of its 52-week range ($7.44 – $40.43). Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.

▸Technical Tape: Trading at 2% of its 52-week range ($7.44 – $40.43) with RSI-14 at 31.5 (OVERSOLD (<32)).
▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $7.72 (no active unusual options sweep snapshot on file).
▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.

Live MPLT Headlines & Catalysts

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MPLT)

✓Walkthrough of MPLT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MPLT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -75.78%🛡️ HOLDING TREND SUPPORT

2026-10-30O $7.70H $7.81L $7.44C $7.72VOL 395.0K

SUP: $6.58SMA50: $10.45SMA200: $20.52

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MPLT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MPLT Butterfly Map → + Track MPLT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MPLT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MPLT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MPLT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MPLT)

Health Care Rank #668 of 1016 ⚔️ OVID vs MPLT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MPLT vs. OVID, CTMX, PHAT, EOLS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, MapLight Therapeutics Inc. (MPLT) ranks #668 by composite RQD confidence (39/100, grade D-) and #451 by equity capitalization ($500.1M). Within this direct 5-issuer industry benchmark cohort, MPLT leads on earnings valuation at N/A trailing P/E, while CTMX leads on capital efficiency and profitability with -20.5% ROIC and — gross margin. PHAT currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with MPLT at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MPLT ACTIVE MapLight Therapeutics Inc.	D-	39/100	—	—	-32.4%	-3.26%	$500.1M	Benchmark Subject
OVID Ovid Therapeutics Inc.	D-	40/100	—	—	-28.5%	+4.49%	$500.0M	/ovid-vs-mplt →
CTMX CytomX Therapeutics Inc.	E	20/100	—	—	-20.5%	-2.97%	$499.0M	/ctmx-vs-mplt →
PHAT Phathom Pharmaceuticals Inc.	D	46/100	—	87.1%	-35.0%	-0.95%	$503.2M	/phat-vs-mplt →
EOLS Evolus Inc.	E	21/100	—	66.3%	-35.0%	-1.51%	$496.7M	/eols-vs-mplt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001770069

In its most recent audited fiscal period (FY2025, filed 2025-12-31), MapLight Therapeutics Inc. (MPLT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$161.2M, operating cash flow of -$138.1M, and free cash flow of -$138.6M (-74.2% YoY). On the balance sheet, MPLT closed FY2025 with $479.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$161.2M	-$138.1M	-$138.6M	$479.5M	—
FY2024 (FY)	2024-12-31	$0	-$77.6M	-$78.8M	-$79.6M	$136.9M	—

3. MPLT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MPLT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, MapLight Therapeutics Inc. (NASDAQ: MPLT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $7.72 (-3.26% 1D, market cap $500.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MPLT ranks #668 in composite RQD confidence.

How does MPLT compare to OVID and CTMX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MPLT carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.4%. By comparison, OVID (Ovid Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -28.5%, cap $500.0M) and CTMX (CytomX Therapeutics Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -20.5%, cap $499.0M). Among the 5-stock peer group, MPLT leads on earnings multiple (N/A) while CTMX leads on capital efficiency (-20.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MPLT?

Per MPLT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001770069), MapLight Therapeutics Inc. generated $0 in revenue, -$161.2M in net income, and -$138.6M in free cash flow against $479.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MPLT trading relative to its 50-day, 200-day, and 52-week technical levels?

MPLT last traded at $7.72 (-3.26% on volume of 156,739 shares), positioning the stock -26.12% below its 50-day simple moving average ($10.45) and -62.38% below its 200-day simple moving average ($20.52). Across its 52-week range of $7.44 to $40.43, MPLT sits at the 0.8% percentile with a 14-day RSI of 31.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($6.76 to $8.68).

MPLT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Why is MPLT stock moving today?

Why MPLT Stock dropped -3.26% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.

Direct Sub-Reports: MPLT RQD Cockpit MPLT 12M Forecast MPLT Earnings & Move MPLT Dividends & DRIP MPLT Insiders & 13F MPLT Whale Options MPLT Profit Sankey MPLT News & Why